A phase I trial of vaccination with autologous, lethally irradiated tumor cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in pediatric and adult patients
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Tumour cell vaccine-GVAX (Primary)
- Indications Adenocarcinoma; Malignant melanoma; Renal cancer; Sarcoma
- Focus Adverse reactions
- 30 Jul 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2018.
- 16 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017.
- 08 Jun 2016 Planned End Date changed from 1 Feb 2016 to 1 Oct 2016.